Clinical Trials
42 trialsPhase II Trial of Zanzalitinib in Patients With Metastatic Castration Resistant Prostate Cancer
Case Comprehensive Cancer Center
Chemical-Shift-Encoded MRI for Active Bone Marrow Dosimetry in Radiopharmaceutical Therapy
University of Wisconsin, Madison
Phase 2a Study of High-Dose Testosterone Followed by Radioligand Therapy in mCRPC
H. Lee Moffitt Cancer Center and Research Institute
AkkPRO
Assistance Publique - Hôpitaux de Paris
CABA-DOC
Gustave Roussy, Cancer Campus, Grand Paris
Autologous Gamma Delta T Cells to Target Prostate Stem Cell Antigen in mCRPC
H. Lee Moffitt Cancer Center and Research Institute
Darolutamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Swiss Cancer Institute
Rad2Nivo
University of Utah
ENCORE
University of Utah
177Lu-HTK03170 in mCRPC With PSMA Positive Disease
British Columbia Cancer Agency
ReaLuP
Hospices Civils de Lyon
PRO-XL
University of Utah
BORXPTEN
University of Utah
Sipuleucel-T Combined With Bipolar Androgen Therapy in Men With mCRPC
Yale University
CaboLu
University of Utah
177Lu-P17-087/177Lu-P17-088 in Patients With Metastatic Castration-resistant Prostate Cancer
Peking Union Medical College Hospital
18F-fluciclovine PET in Metastatic Castration Resistant Prostate Cancer Treated With Life Prolonging Therapies
Tulane University
Phase 1 Trial of SYNC-T - Immunotherapy for Advanced/Metastatic Castration-Resistant Prostate Cancer
Williams Cancer Foundation
A Study of Copanlisib Combined With Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer
Brown University
Ebastine in Combination With Docetaxel as a Treatment for Castration-resistant Metastatic Prostate Cancer
Rigshospitalet, Denmark
LuCAB
Peter MacCallum Cancer Centre, Australia
177Lu-LNC1011 in Patients with Metastatic Castration-resistant Prostate Cancer
Peking Union Medical College Hospital
Circulating Tumor DNA (ctDNA) Monitoring in the Assessment and Prediction of the Efficacy of PARP Inhibitors (PARPi)
Sun Yat-sen University
Open-label Dose Escalation Phase 1b Trial of a New Micellar Docetaxel Compound in Patients With mCRPC
Swiss Cancer Institute
Efficacy and Safety of Organoid-Based Drug Sensitivity Screening to Guide the Treatment of mCRPC Patients Progressed After First-line Treatment
Sun Yat-sen University
177Lu-PSMA-EB-01 in Patients With Metastatic Castration-resistant Prostate Cancer
Peking Union Medical College Hospital
Avelumab Plus 2nd-generation ADT in African American Subjects With mCRPC
Tulane University
DAROTAXEL
Erasmus Medical Center
PORTER
Parker Institute for Cancer Immunotherapy
3TMPO (Triple-Tracer Strategy Against Metastatic Prostate Cancer
Université de Sherbrooke
Total Body PET-CT Imaging of Prostate Cancer Using Illuccix
BAMF Health
Clinical Study on the Efficacy and Safety of RC48-ADC in the Treatment of Metastatic Castration Resistant Prostate Cancer (mCRPC)
Peking University Cancer Hospital & Institute
SHR7390 in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
SPECTacular
BAMF Health
Phase 1 Study of ATRS-2002 in Healthy Male Adults
Syneos Health
Study of Enzalutamide in Patients With Castration-resistant Prostate Cancer
Dana-Farber Cancer Institute
ESCALATE
MANA RBM
Lu177-EB-PSMA617 Radionuclide Treatment in Patients With Metastatic Castration-resistant Prostate Cancer
Peking Union Medical College Hospital
Pamiparib in mCRPC With HRD or BRCA1/2 Mutation
Sun Yat-sen University
Clinical Trial of Selegiline Plus Docetaxel for the Treatment of Metastatic, Castrate-resistant Prostate Adenocarcinoma
University of Pecs
Clinical Trial of Ac225-PSMA Radioligand Therapy of Metastatic Castration-resistant Prostate Cancer
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
177Lu-EB-PSMA617 in Patients With Metastatic Castration-resistant Prostate Cancer
Peking Union Medical College Hospital